[Highly stable regulatory oligopeptides: experience and applications].
Ashmarin. I P IP; Bakaeva. Z V ZV; Vas'kovskiĭ. B V BV; Zheliaznik. N Ia NIa; Zhuĭkova. S E SE; Zolotarev. Iu A IuA; Kamenskiĭ. A A AA; Levitskaia. N G NG; Liapina. L A LA; Miasoedov. N F NF
Key Findings
- Glyprolines are highly stable regulatory peptides that can be absorbed through the gastrointestinal tract.
- In rat studies, glyprolines demonstrated anti‑ulcer, antithrombotic, and antidiabetic activities.
- The activity of related short peptides (PGP, PG, GP) was compared, and potential delivery with connective‑tissue food proteins was explored.
Practical Outcomes
- While the results are intriguing, they are limited to animal models and pre‑clinical stages, so there’s no safe dosage or protocol for humans yet. Biohackers should view glyprolines as a future candidate rather than a current supplement, and await human trials before considering any practical use for gut health, clot prevention, or glucose control.
Summary
Researchers found a new group of tiny proteins called glyprolines that are very stable, can get into the bloodstream when taken by mouth, and showed promising anti‑ulcer, blood‑clot‑preventing, and blood‑sugar‑lowering effects in rats. They compared these to similar short peptides and discussed how they might be mixed with protein‑rich foods for future drug development.
Abstract
The most stable regulatory peptides (RP) including the new family of RP (glyprolines) and derivatives of hybrid peptide MEHFPGP are characterized. High ability of glyprolines to penetrate into the blood-stream through the gastrointestinal tract is demonstrated. Antiulcer, antithrombotic and antidiabetic activities of glyprolines were discovered in experiments on white rats. The activity of oligopeptides PGP, PG and GP is compared. Mechanisms of glycoprolines activities and feasibility of their administration with connective tissue food proteins are discussed. Thus, glyprolines are perspective drugs for treatment of gastric ulcer, correction of hemostasis and thrombosis suppression prepared for preclinical trial.
Study Information
pubmed
2003